AI Tool Supporting Team Treatment Decisions for Non-Small Cell Lung Cancer
Compares AI-suggested treatment plans with team plans in adults with non-small cell lung cancer.
Key facts
- Who runs it
- Wen-zhao ZHONG
- Where
- Guangzhou, ChinaSee the site
- Trial code
- Registry title
- Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Treat Regimen
- Record updated
- 4 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer whose care team has decided they need drug treatment that works through the whole body. It tests an AI tool that suggests treatment plans.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer, not stage I
- Biomarker or test result
- Complete clinical, imaging and molecular pathology data must be available
Main reasons for not taking part
- Stage I disease
- A chest tumor that is not non-small cell lung cancer
- Missing or incomplete medical data
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age ≥ 18 years
- MDT (Multidisciplinary Team) discussion deems a systemic treatment plan necessary
- Complete clinical, imaging, and molecular pathological data
Who cannot take part
- Stage I patients
- Diagnosed with a thoracic tumor other than NSCLC
- Lack of detailed medical data, or missing data
Where in China
- Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Wenzhao Zhong, Dr.Taking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC).
Read full original descriptionShow less
The main questions it aims to answer :
What is the level of agreement between treatment recommendations generated by the AI model and those made by a traditional MDT? How often do clinicians modify their final treatment decision after reviewing the AI model's recommendation? Researchers will compare treatment plans from the traditional MDT (Arm 1), the AI model (Arm 2), and the clinician's final decision after reviewing the AI output (Arm 3) to assess consistency, decision modification rates, and clinical efficiency.
Participants will:
Have their clinical, imaging, and molecular data submitted to both the traditional MDT and the AI model for independent treatment recommendations Receive a final treatment plan determined by clinicians after reviewing both recommendations, with follow-up for safety and survival outcomes
The group in the trial
- AI-Assisted Multidisciplinary Team Decision-Making for Non-Small Cell Lung CancerTreatment being tested
Treatment: Treat Regimen
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC: a Prospective, Controlled Clinical Trial Protocol
- Plain-language title
- AI Tool Supporting Team Treatment Decisions for Non-Small Cell Lung CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 4 June 2026